Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO) have been given a consensus rating of “Hold” by the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $19.83.

BLCO has been the subject of a number of research reports. Royal Bank of Canada reduced their price target on shares of Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday. Stifel Nicolaus reduced their target price on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $22.00 in a report on Wednesday, December 11th. Finally, Bank of America cut their target price on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a research note on Thursday.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors have recently bought and sold shares of the business. Alpine Global Management LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter valued at $181,000. Tang Capital Management LLC grew its holdings in Bausch + Lomb by 28.6% during the 4th quarter. Tang Capital Management LLC now owns 450,000 shares of the company’s stock worth $8,127,000 after acquiring an additional 100,000 shares during the last quarter. Polar Asset Management Partners Inc. increased its position in Bausch + Lomb by 120.4% in the 4th quarter. Polar Asset Management Partners Inc. now owns 33,062 shares of the company’s stock valued at $597,000 after acquiring an additional 18,062 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Bausch + Lomb by 34.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,460 shares of the company’s stock worth $947,000 after acquiring an additional 13,460 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Bausch + Lomb during the fourth quarter worth approximately $735,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Trading Down 0.9 %

Bausch + Lomb stock opened at $15.75 on Monday. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.69. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.95 and a current ratio of 1.60. The firm has a market capitalization of $5.55 billion, a PE ratio of -17.30, a PEG ratio of 2.20 and a beta of 0.46. The business’s 50-day simple moving average is $17.36 and its 200-day simple moving average is $18.17.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the business posted $0.24 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Equities research analysts forecast that Bausch + Lomb will post 0.76 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.